Trial Profile
A clinical study of Favipiravir compared to Arbidol in COVID-19 patients
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 24 Mar 2020
Price :
$35
*
At a glance
- Drugs Favipiravir (Primary) ; Umifenovir
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- 24 Mar 2020 New trial record
- 19 Mar 2020 Results(n=240) published in the Zhejiang Hisun Pharmaceutical Media Release.